[Sofia, Bulgaria] – Comac Medical is pleased to announce that Steve Angus will be joining Comac Medical as our new Chief Financial Officer (CFO), effective September 1st.
Steve brings with him more than 20 years of experience in financial leadership roles within the healthcare and life sciences industries. Most recently, he served as Vice President of Finance – Clinical Operations at IQVIA, where he led global financial strategy for a business unit delivering billions of dollars in annual service revenue.
His distinguished career includes senior roles at IQVIA Biotech, as well as leadership positions at Cardtronics UK and Saracens RFC, all following a strong foundation built in Audit and Assurance roles at Deloitte UK.
A Proven Leader in Financial Strategy
Throughout his career, Steve has been recognized for driving financial performance, enhancing operational efficiency, and fostering cross-functional collaboration in global settings. His experience leading complex financial operations at scale will be instrumental as we continue our mission to strengthen Comac Medical’s position in the global clinical research landscape.
Strengthening Our Future
Steve’s appointment marks an exciting step in our growth journey. His deep expertise and strategic mindset will be pivotal in shaping the financial direction of Comac Medical as we expand and innovate in support of our partners and patients worldwide.
We are delighted to welcome Steve to the Comac Medical family and look forward to the impact he will make within our leadership team.
About Comac Medical
Comac Medical is a leading clinical research organization (CRO) and site management organization (SMO) with 27 years of experience in delivering high-quality solutions for clinical trials. Headquartered in Bulgaria, the company offers a full range of services across all phases of drug development, specializing in clinical operations, data management, regulatory affairs, and site management. Comac Medical partners with global pharmaceutical, biotechnology, and medical device companies to drive innovation, operational excellence, and improved patient outcomes, ensuring successful and efficient trial execution.
